DURHAM, N.C., Nov. 18, 2015 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, has been chosen by Informa as one of the 2015 Top 10 Immuno-Oncology Companies to Watch. Anil Goyal, Ph.D., Heat's Vice President of Business Development, will present at the 10th Annual Therapeutic Area Partnerships meeting on November 18-20, 2015 at the Hilton Back Bay in Boston. Dr. Goyal's presentation is scheduled on Thursday, November 19, 2015 at 1:15 p.m. Eastern Time.
"We are honored that Informa has selected us amongst the rapidly evolving and dynamic immuno-oncology field. Heat's ImPACT and ComPACT platform technologies are designed to activate CD8+ killer T cells; enhance T cell co-stimulation; and are combinable with checkpoint immunotherapies which reverse tumor-induced immune suppression. We believe these three mechanisms of action are essential to an effective anti-tumor response," said Dr. Goyal. "We most recently announced positive Phase 1 data for our lead product candidate, HS-410, for non-muscle invasive bladder cancer, reporting that it elicited a high level of CD8+ tumor-infiltrating lymphocytes following vaccination. A Phase 2 trial for HS-410 is ongoing and we expect topline efficacy, immune-response and safety data in the fourth quarter of 2016."
About the Therapeutic Area Partnerships (TAP)
Since its launch ten years ago, TAP has come to be regarded as the industry's premier boutique partnering event. A uniquely efficient gathering, TAP brings together decision-makers to assess the most promising drug programs available for partnering in: Cardiovascular/Metabolic Diseases, Neuroscience, Anti-Inflammatory/Autoimmune Diseases, Oncology/Immuno-Oncology, Infectious and Emerging Diseases, Advanced Therapies (Cell, Gene & Stem Therapies), Orphan and Rare Diseases, and Academic Technology Transfer.
Attendees have the opportunity to hear from and meet some of the industry's most talented biotechnology entrepreneurs and pharmaceutical leaders. Casual gatherings and one-on-one partnering meetings bring together business development decision makers from large pharmaceutical firms and executive leadership from innovative biotechnology firms to make this one of the industry's most productive events.
For more information, visit: http://www.iirusa.com/therapeuticareapartnership/home.xml.
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer. Heat's highly specific T cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ "killer" T cells (one of the human immune system's most potent weapons against cancer); T cell co-stimulation to further enhance patients' immune response; and reversal of tumor-induced immune suppression. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC).
For more information please visit www.heatbio.com.
Forward Looking Statements
This press release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding ImPACT and ComPACT platform technologies' potential as therapies, the three mechanisms of action essential to an effective anti-tumor response, the timing of the HS-410 topline efficacy, immune-response and safety data expected in the fourth quarter of 2016. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability of Heat's ImPACT and ComPACT therapies to perform as designed, the ability to enroll patients and complete the clinical trials on time, the other factors described in our annual report on Form 10-K for the year ended December 31, 2014 and Heat's other filings with the SEC. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
CONTACT: Heat Biologics, Inc. Jennifer Almond Investor and Media Relations 919-240-7133 email@example.com